Objective To study the local efficacy of ultrasound-guided interstitial implantation of radioactive 125I seeds in the treatment of hepatic tumors at dangerous sites.Methods A retrospective study was conducted on 39 patients who were admitted into the First Medical Center,PLA General Hospital from November 2011 to January 2018.There were 23 males and 16 females.A three-dimensional planning before 125I seed implantation was performed for all these patients using the treatment planning system (TPS).The implantation was performed under ultrasound guidance.Liver CT scan was performed in all the patients after implantation to evaluate the actual distribution of the seeds in the tumors.Follow-up was performed at 2,4,6,9 and 12 months after implantation,respectively,to evaluate using complete response (CR),partial response (PR),steady disease (SD),progressive disease (PD) and local control rates (LCR).Results Implantation was successfully performed in all the 39 patients.CT scan showed that 5 patients (12.8％)required additional implantation.Follow-up imaging after implantation showed local control of the lesions was good.The rates of CR,PR,SD and LCR were 2.6％ (1/39),28.2％ (11/39),66.7％ (26/39) and 97.4％ (38/39),respectively.One patient (2.6％,1/39) showed local progressive disease.The LCR reached 97.4％ (38/39) at 12 months of follow-up.Conclusion Ultrasound-guided radioactive 125I seed implantation was efficacious in the treatment of hepatic tumors at dangerous sites.

Objective:To evaluate the long-term efficacy of percutaneous microwave ablation (MWA) therapy for hepatocellular carcinoma.Methods:2054 cases with Barcelona Clinic Liver Cancer (BCLC) stage 0~B at the Fifth Medical Center of the Chinese People's Liberation Army General Hospital from January 2006 to September 2020 were retrospectively collected. All patients were followed up for at least 2 years. The primary endpoint of overall survival and secondary endpoints (tumor-related survival, disease-free survival, and postoperative complications) of patients treated with ultrasound-guided percutaneous MWA were analyzed. Kaplan-Meier method was used for stratified survival rate analysis. Fine-and-Gray competing risk model was used to analyze overall survival.Results:A total of 5 503 HCC nodules [mean tumor diameter (2.6±1.6) cm] underwent 3 908 MWAs between January 2006 and September 2020, with a median follow-up time of 45.6 (24.0 -79.2) months.The technical effectiveness rate of 5 375 tumor nodules was 97.5%. The overall survival rates at 5, 10, and 15-years were 61.6%, 38.8%, and 27.0%, respectively. The tumor-specific survival rates were 67.1%, 47.2%, and 37.7%, respectively. The free tumor survival rates were 25.8%, 15.7%, and 9.9%, respectively. The incidence rate of severe complications was 2.8% (108/3 908). Further analysis showed that the technical effectiveness and survival rate over the passing three time periods from January 2006-2010, 2011-2015, and 2016-September 2020 were significantly increased, with P ?